2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2015-1-4-5-12405Medicine (miscellaneous)CLINICAL EFFICIENCY OF AZILEKT IN THE THERAPY OF PRIMARY PROGRESSING MULTIPLE SCLEROSISCLINICAL EFFICIENCY OF AZILEKT IN THE THERAPY OF PRIMARY PROGRESSING MULTIPLE SCLEROSISGubarevYuri D.GubarevYuri D.gubarev@bsu.edu.ruYatsenkoEugene A.YatsenkoEugene A.yatsenko_ea@bsu.edu.ruChefranovaZhanna Yu.ChefranovaZhanna Yu.20151400

Multiple sclerosis − the chronic multifactorial progressing autoimmune disease of the central nervous system developing at any age, but mainly in young people. One of the factors of progression, along with the demyelination process is axonal degeneration and imminent death of the cell body. Currently, scientists are actively searching for new drugs for the treatment of MS, the drugs that can inhibit proapoptotic factors and activate the anti-apoptotic molecules. In the capacity of a drug with similar effects on patients, we used the drug Azilekt (TEVA) which affects the process of preventing the nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase, the activation of anti-apoptotic molecules, the suppression of proapoptotic factors and conservation capacity of mitochondria. We have revealed that the use of the drug Azilekt as a cytoprotective therapy in patients suffering from secondary progressive multiple sclerosis is likely to improve the effectiveness of treatment and quality of life of patients.

Multiple sclerosis − the chronic multifactorial progressing autoimmune disease of the central nervous system developing at any age, but mainly in young people. One of the factors of progression, along with the demyelination process is axonal degeneration and imminent death of the cell body. Currently, scientists are actively searching for new drugs for the treatment of MS, the drugs that can inhibit proapoptotic factors and activate the anti-apoptotic molecules. In the capacity of a drug with similar effects on patients, we used the drug Azilekt (TEVA) which affects the process of preventing the nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase, the activation of anti-apoptotic molecules, the suppression of proapoptotic factors and conservation capacity of mitochondria. We have revealed that the use of the drug Azilekt as a cytoprotective therapy in patients suffering from secondary progressive multiple sclerosis is likely to improve the effectiveness of treatment and quality of life of patients.

multiple sclerosistherapyazilektautoimmune reactiondemiyelizatsiyaaksonalny degenerationEDSS scalemultiple sclerosistherapyazilektautoimmune reactiondemiyelizatsiyaaksonalny degenerationEDSS scaleСписок литературы1.                Gusev E.I., Zavalishin I.A., Boiko A.N. / Multiple Sclerosis and other Demyelinating Diseases // Moscow: Miklos. 2004. 540 p.2.                Duus AP / Topical Diagnosis in Neurology. Anatomy. Physiology. Clinic. // Moscow: CPI "Vasari Ferro"  1997. 400 p.3.                Ilves A.G., Prakhova L.N., Kataeva G.V. et al. / Changes in Glucose Metabolism of the Brain in Patients with Multiple Sclerosis and their Role in Shaping the Clinical Development and Progression of the Disease. // S.S. Korsakov Journal of Neurology and Psychiatry. 2003. Spec. release. Multiple Sclerosis, №2. Pp.53-60.4.                Reznikov T.N., Terentyev I.Y., Kataeva G.V., Ilves A.G. / PET scan of the Human Brain and Psychological Defense Mechanisms of the Individual Patients with Multiple Sclerosis. // Human Physiology.  2004.  Volume 30, №4  Рp. 25-315.                Ilves A.G., Prakhova L.N., Kataeva G.V. et al. / Changes in Glucose Metabolism of the Brain in Patients with Multiple Sclerosis and their Role in Shaping the Clinical Development and Progression of the Disease. // S.S. Korsakov Journal of Neurology and Psychiatry. 2003. Spec. release. Multiple sclerosis, №2. Pр.53-60.6.                Mikhail Salnikov, Choline A.V., Bondarev E.V. / Magnetic Resonance Imaging of Multiple Sclerosis // Terra Medica. 1998. Volume 4. Pp. 28-30.7.                Gusev E.I., Demin T.L., Boiko A.N. / Multiple Sclerosis. // M. 1997.8.                Medical portal: Medzona.info Access: URL: http://medzona.info/lekarstva/aa/164-azilekt-azilect.html (date of access: October 16, 2015).9.                Yevtushenko S.K., Derevyanko I.N, Kohut A.I. Dissociation of the Clinical Picture and the Intensity of Demyelinating Lesions in Multiple Sclerosis // Proceedings of the 9th Annual Symposium of the Russian Society of Multiple Sclerosis. May 25-29, 2000, St. Petersburg. Рp. 46-48.10.           Vorobyov N.L. Demkina V.A., Gervazieva V.B. Features of Antiviral Immunity in Patients with Multiple Sclerosis // Neuroimmunology.  Volume 3, №1. 2005. P. 28-32.11.           Zawadzka M., Franklin R.J. / Myelin regeneration in demyelinating disorders: new developments in biology and clinical pathology. // Curr Opin Neurol. 2007. vol.20 (3) p.294-298.12.           Kurtzke J.F. / Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). // Neurology. 1983. Vol. 33. №12. P. 1444-1452.13.           Ayers M.M., Hazelwood L.J., Catmull D.V. et al. / Early glial responses in murine models of multiple sclerosis. // Neurochem Int.  2004. vol.45 (2-3)  p.409-419.